Invictus MD Strategies (Invictus MD Strategies) 3-Year Dividend Growth Rate : 0.00% (As of Oct. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Invictus MD Strategies 3-Year Dividend Growth Rate?

Invictus MD Strategies's Dividends per Share for the three months ended in Oct. 2019 was $0.00.

The historical rank and industry rank for Invictus MD Strategies's 3-Year Dividend Growth Rate or its related term are showing as below:

IVITF's 3-Year Dividend Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 9.1
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Invictus MD Strategies's Dividend Payout Ratio for the three months ended in Oct. 2019 was 0.00. As of today, Invictus MD Strategies's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Invictus MD Strategies's 3-Year Dividend Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Invictus MD Strategies's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invictus MD Strategies's 3-Year Dividend Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Invictus MD Strategies's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Invictus MD Strategies's 3-Year Dividend Growth Rate falls into.

Invictus MD Strategies 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Invictus MD Strategies (OTCPK:IVITF) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Invictus MD Strategies's Dividend Payout Ratio for the quarter that ended in Oct. 2019 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Oct. 2019 )	/	EPS without NRI (Q: Oct. 2019 )
	=	0	/	-0.045
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invictus MD Strategies 3-Year Dividend Growth Rate Related Terms>

Invictus MD Strategies (Invictus MD Strategies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Invictus MD Strategies Corp (OTCPK:IVITF) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

595 Burrard Street, 16th floor, Vancouver, BC, CAN, V7X 1J1

Website

http://www.invictus-md.com

Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.